Bluejay Therapeutics, Inc. — Form D
Bluejay Therapeutics, Inc. of SAN MATEO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2021-06-21. The offering totals $24.2M, of which $19.2M was reported sold. Industry: Other Technology.
Offering
- Filed: 2021-06-21
- Form: D
- Accession: 0001868267-21-000001
- Industry: Other Technology
- Exemptions: 06b
- Total offering: $24.2M
- Amount sold: $19.2M
- Remaining: $5.0M
- Investors: 6
- Date of first sale: 2021-06-10
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-403422
Issuer
- Name: Bluejay Therapeutics, Inc.
- CIK: 0001868267
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 400 CONCAR DRIVE, SUITE 3-101, SAN MATEO, CA, 94402
- Phone: 650-218-5487
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Dan Estes | Director | Redwood City, CA |
| Alon Lazarus | Director | Cambridge, MA |
| Wen Chen | Director | New York, NY |
| Pascal Krotee | Director | SAN MATEO, CA |
| Jianqing Li | Director | SAN MATEO, CA |
| Keting Chu | Director | SAN MATEO, CA |
| Keting Chu | Executive Officer | SAN MATEO, CA |
| Dajun Yang | Director | SAN MATEO, CA |
| Nancy Hong | Director | Philadelphia, PA |
| William J Rutter | Director | San Francisco, CA |
| Ting J Jia | Director | New York, NY |
Other filings by this issuer (2)
More